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Diabetes mellitus causes a large majority of non-traumatic major and minor 
amputations globally. Patients with diabetes are clinically complex with a 
multifactorial association between diabetic foot ulcers (DFU) and subsequent 
lower extremity amputations (LEA). Few studies show the long-term outcomes 
within the cohort of DFU-associated LEA.
AIM 
To highlight the long-term outcomes of LEA as a result of DFU.
METHODS 
PubMed/MEDLINE and Google Scholar were searched for key terms, “diabetes”, 
“foot ulcers”, “amputations” and “outcomes”. Outcomes such as mortality, re-
amputation, re-ulceration and functional impact were recorded. Peer-reviewed 
studies with adult patients who had DFU, subsequent amputation and follow up 
of at least 1 year were included. Non-English language articles or studies 
involving children were excluded.
RESULTS 
A total of 22 publications with a total of 2334 patients were selected against the 
inclusion criteria for review. The weighted mean of re-amputation was 20.14%, 
29.63% and 45.72% at 1, 3 and 5 years respectively. The weighted mean of 
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mortality at 1, 3 and 5 years were 13.62%, 30.25% and 50.55% respectively with 
significantly higher rates associated with major amputation, re-amputation and 
ischemic cardiomyopathy.
CONCLUSION 
Previous LEA, level of the LEA and patient comorbidities were significant risk 
factors contributing to re-ulceration, re-amputation, mortality and depreciated 
functional status.
Key Words: Lower extremity amputations; Long-term outcomes; Diabetic foot ulcers; 
Quality of life; Re-amputation; Diabetes
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Core Tip: There was a significantly higher degree of re-amputation and mortality in those 
who undergo amputations due to diabetic foot ulcers in addition to impact on quality of 
life. Data on long-term outcomes in these patients were limited and requires further 
research to better understand the long-term outcomes in this subset of patients.
Citation: Rathnayake A, Saboo A, Malabu UH, Falhammar H. Lower extremity amputations 





Diabetes mellitus is a leading cause for non-traumatic major and minor amputations 
worldwide. The global diabetes prevalence is expected to rise to 10.2% by 2030, 
reflecting a considerable health and financial burden across the world due to its 
recognised aetiology in lower extremity amputations (LEA)[1]. The combination of 
peripheral neuropathy and vascular disease gives rise to diabetic foot ulcers (DFU) 
subsequently leading to a higher rate of LEA. LEA is defined as surgical removal of 
bones and soft tissue by transecting at any level of the lower extremity and can be 
classified into minor and major amputation. The globally accepted definition of minor 
amputation is below ankle joint encompassing forefoot and toe while major 
amputations are at or proximal to the ankle joint such as below or above knee 
amputation.
The associated immunosuppression as well as impaired blood flow to DFU make 
conservative treatment with antibiotics difficult and usually mandate extensive, 
repeated debridement or eventual amputation. Patients with diabetes have a varied, 
yet overall increased risk of LEA with an incidence of 50-500 per 100000[2]. The short- 
and long-term outcomes as a result of LEA are profound, as patients with diabetes 
often have complex comorbidities and socioeconomic backgrounds. Short-term 
outcomes following LEA are poor, with early post-operatively mortality up to 22%[3]. 
There is currently no systematic review nor meta-analysis published in this field.
The objective of this systematic review and meta-analysis was to elucidate the long-
term outcomes in diabetic patients who have LEA as a result of an ulcer. Outcomes 
such as mortality, re-amputation, re-ulceration and functional return are discussed 
with an emphasis of associated risk factors.
MATERIALS AND METHODS
The authors performed a systematic review of electronic databases and peer-reviewed 
sources including PubMed/MEDLINE up to March 25, 2020. Key search terms 
“Diabetes”, “Foot Ulcers”, “Amputations” and “Outcomes” were used and the authors 
hand searched each identified manuscript for pertinent references. The inclusion 
criteria were as follows: (1) Age > 18 years; (2) Presence of DFU prior to undergoing an 
amputation; and (3) Outcomes measured at longer than at least 12 mo. The exclusion 
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criteria was limited to studies relating to paediatric patients. Only English language 
studies with original data were included with no restriction on publication date. 
Duplicate results were excluded. Each study was assessed for selection by two 
individual authors with a plan for escalation to corresponding authors, should there 
be a disagreement. No studies required further consensus. Statistical analysis looking 
at weighted mean age, rates of mortality at 1, 3 and 5 years and re-amputation were 
calculated. Individual studies were examined for bias, in particular, selection, attrition 
and recall bias. Significant loss to follow up, degree of heterogeneity and presence of 
confounding factors were examined. The PRISMA 2009 Checklist was followed. No 
conflict of interests are declared with no external funding sought for this study.
RESULTS
Key search terms yielded a total of 125 results of which 22 publications were selected 
against the inclusion and exclusion criteria for review. Of the selected studies, 11 
studies were prospective, 8 retrospective, 3 systematic review and meta-analyses 
(Table 1). Overall, the majority of selected articles were level III evidence but ranged 
from level II-V and no randomized controlled trials were found. Sixteen of the 18 
studies conducted standardisation of the patient cohort with regards to co-morbidities. 
In the 9 prospective studies, only three studies had any loss of follow up in patients 
(range 5%-20%).
Rates of re-ulceration were reported to be higher in patients with history of LEA 
and DFU compared to conservative management in both ipsilateral and contralateral 
limbs. The weighted mean was calculated for both re-amputation and mortality. A 
total of 9 articles reported rates of re-amputation of which only 2 articles specified 
rates at 1, 3 and 5 years. With the exclusion of 2 publications, all articles were 
published after 2001 and the calculated weighted mean of re-amputation was 20.14%, 
29.63% and 45.72% at 1, 3 and 5 years respectively (Table 2). A total of 8 articles specify 
mortality outcomes at 1, 3 and 5 years, of which, only 2 articles were published prior to 
2001 (Table 3). The cumulative total of 994 patients found a mean age of 70.2 years and 
exhibited a male predominance. The weighted mean mortality at 1, 3 and 5 years were 
13.62%, 30.25% and 50.55% respectively and were only calculated using the studies 
which specified each interval's long-term outcome.
DISCUSSION
There is a paucity of data pertaining to long-term outcomes of patients with DFU-
associated LEA. Few studies exceed 5 years with the longest study assessing outcomes 
just over 10 years. The main outcomes of this systematic review and meta-analysis 
found a weighted mean of mortality at 1, 3 and 5 years were 13.62%, 30.25% and 
50.55% respectively and weighted mean of re-amputation at 1, 3 and 5 years were 
20.14%, 29.63% and 45.72% respectively. Major amputation was found to be a negative 
prognostic factor for return to activities of daily living.
Re-ulceration
Patients with a previous LEA for DFU have a higher risk of re-ulceration than patients 
undergoing conservative treatment for DFU. In a 4-year follow-up study, 40% of 
patients with previous LEA had re-ulceration at 1 year compared to 30% of the non-
LEA group. At the 3 and 5-year mark, the ulcer recurrence was 70% and 75% in the 
LEA group compared to 52% and 60% in the non-LEA group[4]. Following LEA, there 
is a high risk of re-ulceration of both the ipsilateral and contralateral limb with the 
former being higher. In a 5-year follow-up study of 245 patients who had undergone 
toe amputation for DFU, the cumulative incidence of a new foot ulcer at 1,3 and 5 
years was 27.3%, 57.2% and 74.4% respectively. The rate of ulceration in the 
contralateral limb has been shown to be as high as 23%[5].
Re-amputation
Previous LEA is an important, independent risk factor for further amputations. The 
earliest studies in the late 1990s examining re-amputations in patients involved rates 
as high as 60% over 10 years in 90 patients with a Swedish study of 189 patients 
reporting re-amputation rates at 14%, 30% and 49% at years 1, 3 and 5 after the index 
LEA[6,7].
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Table 1 Follow-up, nature, and presence of standardisation in selected studies
Ref. Number of patients lost to follow up (5) Nature of study Standardisation for comorbidities
Chu et al[12] 17 (6.9) Prospective Standardised
Larrson et al[7] 0 Prospective Not standardised
Schleiffer et al[23] 0 Prospective Standardised
Faglia et al[20] 0 Prospective Standardised
Van Damme et al[13] 0 Prospective Standardised
Goldner et al[5] NS Prospective Standardised
Morbach et al[16] 0 Prospective Standardised
Ghanassia et al[8] 5 (5) Prospective Standardised
Skoutas et al[10] 0 Prospective Standardised
Adler et al[24] 155 (2) Prospective Standardised
Ohsawa et al[25] 0 Prospective Standardised
Izumi et al[9] N/A Retrospective Standardised
Murdoch et al[6] N/A Retrospective Standardised
Uzzaman et al[26] N/A Retrospective Standardised
Acar et al[11] N/A Retrospective Standardised
Nerone et al[17] N/A Retrospective Standardised
Aulivola et al[27] N/A Retrospective Not standardised
Jeyaraman et al[18] N/A Retrospective Standardised
Jeyaraman et al[21] N/A Retrospective Standardised
Thorud et al[15] N/A Meta-analyses Standardised
Albers et al[28] N/A Meta-analyses Standardised
Borkosky et al[14] N/A Systematic Review Standardised
NS: Not specified; N/A: Not applicable.
More recently, in a study of 39 patients over 6.5 years, the re-amputation rate 
remained high at 55.6%[8]. This high rate was also observed over time in another study 
of 277 patients over 10 years where re-amputation at 1, 3 and 5 years was 26.7%, 48.3% 
and 60.7%[9]. Other studies show a lower re-amputation rate. A re-amputation rate of 
21.5% in a study of 121 patients , 16.7% in 132 patients following DFU-related LEA and 
12.5%, 22.3% and 47.1% in 245 patients at 1, 3 and 5 years[10-12].
There is conflicting evidence regarding the role of the index LEA in the risk of 
subsequent re-amputation. Murdoch et al[6] in the 1990s first illustrated that a large 
proportion of patients with an LEA at the level of the great toe or ray amputation 
received a higher-level amputation in the first 12 mo[6]. In 146 patients over a 5-year 
follow up period, a higher rate of re-amputation was observed in primary toe 
compared to a more proximal forefoot index LEA (28% vs 24%)[13].
A systematic review conducted by Borkosky et al[14] of 435 index ray amputations 
showed a re-amputation incidence of 19.8% over a mean follow-up of 26 mo. In 
response to this high rate of re-amputation, Throud et al[15] assessed the viability of a 
more proximal transmetatarsal amputation. A higher rate of 29.7% was observed in 
this systematic review of 1453 patients. The most statistically significant difference, 
however, was seen in 121 patients assessed by Skoutas et al[10] In this study with a 
follow-up of 18 mo, re-amputation rate following a toe and ray amputation were 
significantly higher compared to an index major LEA at all 1, 3 and 5 years. Overall, 
the rate of ipsilateral re-amputation significantly reduced by 34% as the level of the 
original LEA went higher.
However, the Swedish study in 1998 showed no difference in rate of re-amputation 
following an index major or minor LEA[7]. Similarly, in another study of 247 patients, 
there was no statistical difference in re-amputation rate regardless of the nature of 
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Table 2 Re-amputation at 1, 3 and 5 years in patients who previously had had a lower extremity amputation due to diabetes foot ulcer
Re-amputation, %
Ref. Year n
1 yr 3 yr 5 yr
Acar et al[11] 2017 132 NS 22 N/A
Uzzaman et al[26] 2016 79 NS NS 13.9
Chu et al[12] 2014 245 12.5 22.3 47.1
Skoutas et al[10] 2009 121 21.5 N/A N/A
Ghanassia et al[8] 2008 39 NS NS 55.6
Izumi et al[9] 2006 277 26.7 48.3 60.7
Faglia et al[20] 2001 80 0 0 0
Murdoch et al[6] 1997 90 NS NS 60
Hosch et al[29] 1997 35 63 N/A N/A
Weighted, mean ± SD 20.14 ± 3.55 29.63 ± 8.35 45.72 ± 9.09
NS: Not specified; N/A: Not applicable.
Table 3 Mortality at 1, 3 and 5 years in patients who previously had had a lower extremity amputation due to diabetes foot ulcer
Mortality, %
Ref. Year n Mean age Male, %
1 yr 3 yr 5 yr
López-Valverde et al[30] 2018 203 72 78 9.4 27.2 44.5
Uzzaman et al[26] 2016 79 75 64.5 15.6 25 27
Chu et al[12] 2014 245 69.27 53 5.8 15.1 32.7
Morbach et al[16] 2012 38 68.8 58.7 15.4 33.1 45.8
Ghanassia et al[8] 2008 39 63.8 69.7 12 35 44
Faglia et al[20] 2001 80 63.4 73 33.3 51.9 74.1
Larrson et al[7] 1998 187 72 56 15 38 68
Apelqvist et al[4] 1993 123 70 55 20 41 73
Weighted, mean ± SD 13.62 ± 0.92 30.25 ± 2.12 50.55 ± 4.13
index LEA in the follow up period of 10 years[16]. With regards to contralateral re-
amputation, the level of index LEA was also not statistically significant. The effect of 
the level of index LEA on subsequent re-amputation can be extremely useful in clinical 
decision making and have a significant effect on patient outcomes. Larger cohorts are 
needed to establish a meaningful association or lack thereof between index level LEA 
and re-amputation. In addition, recording the time of subsequent amputations may 
provide further insight into differences between type of index amputation and the 
interval time to re-amputation.
The presence and severity of peripheral arterial disease (PAD) was also seen as a 
significant risk factor in the need for re-amputation. In a study of 163 patients with an 
index DFU-associated LEA, rates of re-amputation were significantly related to the 
presence and severity of PAD[17]. Over a mean follow-up of 3.65 years, these patients 
either had a subsequent major or minor re-amputation. A higher proportion of the 
major group (111 patients) had PAD compared to in the minor (52 patients) group 
(71.15% vs 22.23%; P < 0.001). Furthermore, there was a significantly decreased interval 
to a major amputation if PAD was present and whether it was mild to moderate (1.62 
years) or severe (1.53 years) than if no PAD (3.24 years).
An Australian study done by Jeyaraman et al[18] of 513 patients with DFU with a 
mean follow-up of 5.8 years showed prior LEA was an independent factor to 
subsequent re-amputation. In the 263 patients who had a LEA, 85 (32.3%) had a prior 
LEA which was statistically significant. The odds ratio (OR) for any subsequent LEA 
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was 4.49 (95% confidence interval 1.69-11.9), further broken down into 4.84 in the 
minor group and 3.06 for a subsequent major LEA.
Mortality
We found a total of 8 articles which had reported on up to 5-year mortality in patients 
undergoing major and minor amputations secondary to DFU with interval data at 1, 3 
and 5 years (Table 2). The weighted mean mortality at 1, 3 and 5 years were 13.62%, 
30.25% and 50.55% respectively (Table 3). Furthermore, six other studies illustrated 
similar mortality at varied follow-up periods ranging from 1 to 10 years. Comparable 
3-year mortality was reported by Nerone et al[17] and Ramsey et al[19] of 28.85% and 28% 
respectively.
Chu et al[12] (2014) is the largest study to date which observed 245 patients for 5 years 
post DFU-associated LEA and reported the cumulative mortality of 5.8%, 15.1% and 
32.7% at 1, 3 and 5 years respectively. The overall all-cause mortality in this study was 
37.8% with an average survival time for deceased patients of 3.8 years and a longer 
duration of survival in females (4.1 years). Cause of death varied including foot-
related deaths (25.7%), renal failure (22.9%), heart failure (18.6%) and malignancy 
(17.1%). Age > 70, poor glycemic control (HbA1c > 9, P < 0.01), critical limb ischemia 
(OR = 5.60; 95%CI: 2.41-12.98, P < 0.01), diabetic nephropathy (OR = 3.86; 95%CI: 1.65-
9.03; P < 0.01), level of amputation and re-amputation were identified as independent 
risk factors for impaired wound healing, re-ulceration, re-amputation and mortality.
The level and previous history of amputation were observed as risk factors. In 
Larson et al[7], a statistically significant higher mortality was observed following major 
index LEA than minor. Overall, mortality rates at 1, 3 and 5 year were also higher than 
previous studies (15%, 38% and 68%) respectively. Apelqvist et al[4] (1993) reported a 
higher long-term (1, 3 and 5 year) mortality rate among patients with a previous 
amputation from a diabetic foot ulcer compared to new, primary amputation (20%, 
41%, 73% vs 8%, 27%, 42%).
Faglia et al[20] reported higher rates of mortality at each interval 33.3%, 51.9% and 
74% of which ischemic cardiomyopathy was identified as the most frequent cause of 
death. A large proportion (47%) of this study population were affected with ischemic 
cardiomyopathy unlike a much smaller percentage reported in previous studies. 
Subsequently, it is an important independent patient characteristic to consider when 
assessing risk in patients undergoing LEA with DFU given there were no re-
amputations in this cohort. Chu et al[12] also reported ischemic heart disease (HR = 1.6, 
95%CI: 1.1-2.4) in addition to deeper ulcers with bone involvement (HR = 1.5, 95%CI: 
1.2-1.7) as positive predictors for death.
In the Australian study of 513 patients conducted by Jeyaraman et al[21], there were 
199 deaths during a mean follow-up of 5.8 years. The 5-year mortality was recorded at 
24.6%, increasing to 45.4% at the 10-year mark. Of note, these patients died at an 
average age of 64.6 years, significantly lower than the Australian average of 80.4 years 
males and 84.5 years in females.
The 14 studies describing mortality post DFU-associated LEA fall within 
comparable ranges, however, some variability noted is due to smaller cohort sizes and 
presence of ischemic cardiomyopathy in particular.
Effect on the activities of daily living
There is limited data available describing the functional outcomes in patients 
undergoing DFU-associated LEA. Although such a cohort of patients invariably have 
complex socioeconomic backgrounds and variable demographics, our search yielded 
two studies with relatively objective measures of functional status.
Re-amputation has been noted to play an important role in return to functional 
status in long-term studies. Chu et al[12] examined the long-term impact on activities of 
daily living based on Barthel Index Classification (BIC). The Barthel Index of Activities 
of Daily Living is a simple tool measuring functional independence[22]. It comprises 10 
separate sections of assessment with a total score of 100 and can be easily administered 
by health-care professionals. This is a world-wide accepted tool and has been utilized 
in a large number of studies. Chu et al[12] reported 31.9% of patients having moderate to 
severe dysfunction, assessed by the BIC, of the activities of daily living at 5 years. 
Furthermore, 77.9% of these patients had undergone re-amputation and 54.2% had 
died. In contrast, the remaining 126 patients considered to have no or mild 
dysfunction of activities of daily living had lower rates of re-amputation (34.9%) and 
mortality (30.2%). Of note, there was a higher ratio of major to minor amputations in 
the moderate to severe dysfunction group compared to no or mild dysfunction group 
[24 (major):22 (minor) vs 12 (major):32 (minor)].
Van Damme et al[13] reported that only 63% of the major amputations (n = 143) 
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regained an autonomic walking capability with their prosthesis suggesting poor 
functional recovery after major amputations undertaken for DFUs. As well as 
functional status, an important measure of lifestyle change in hospitalized patients is 
discharge destination. Larson J et al[7] reported a statistically significant difference in 
discharge following minor and major patients in 187 patients. In the minor group, 93% 
of patients returned home compared to only 62% in the major group (P < 0.001). 
Patients who underwent minor amputations also had a higher chance of satisfactory 
return to baseline function. In patients with a considerable walking capacity (> 1 km) 
prior to amputation, 49 of 68 patients (72.1%) who had a minor amputation regained 
this capacity compared to only 5 of the 28 patients (17.8%) with major amputation (P < 
0.001).
The present study has several limitations. As this systematic review examined 
studies from a myriad of social backgrounds with variable demographics, 
heterogeneity in the studied population could not be avoided. The variable duration of 
follow-up also added to this heterogeneity, adding to the challenge to derive 
conclusions to specific groups of patients. Approximately 50% of the studies in our 
systematic review were retrospective, predisposing outcomes to historical or recall 
bias. Patients lost to follow-up could also potentially underestimate adverse outcomes 
leaning from the hypothesis of selection bias that such patients are less likely to be 
compliant with glucose monitoring. Similarly, non-participation at the start in 
prospective studies also represents a gap in outcomes from that particular cohort. The 
indications for re-amputation were not clearly noted in the examined studies making 
the cause-and-effect relationship from a previous amputation less reliable. Reporting 
of comorbidities was also patchy across studies making standardised conclusions 
difficult.
In conclusion, there was a significantly higher degree of re-amputation and 
mortality in the long-term in the population who undergo amputations due to diabetic 
foot ulcers. There was also a significant impact on the overall functional status of 
patients and quality of life. This systematic review and meta-analysis affirms the need 
for regular review and follow-up in this vulnerable group owing to this high risk of 
adverse outcomes. The effect of comorbidities was not clear and therefore further 
studies in a subset of patients with particular coexisting illnesses such as chronic 
kidney failure or peripheral vascular disease are needed.
ARTICLE HIGHLIGHTS
Research background
There is no previous systematic review and meta-analysis undertaken particularly in 
long-term outcomes of patients who undergo lower limb amputation (LEA) for 
diabetic foot ulcers (DFU). Although multiple studies describing short-term outcomes 
under 12 mo are available, conclusions for long-term outcomes are needed to support 
clinical decision-making in relation to patient characteristics.
Research motivation
Since DFU account for significant complications in patients with diabetes mellitus, the 
assessment of their long-term outcomes is necessary. The review of long-term 
outcomes following LEA is essential for decision-making and risk stratification for 
individual patients.
Research objectives
The aim of this paper is to establish a systematic review of long-term studies 
undertaken in patients who underwent LEA as a treatment modality for DFU. The 
focus of the review is on re-ulceration, re-amputation and the impact on the quality of 
life of patients. These parameters, particularly in the longer-term setting pave way for 
future research in larger cohorts, various demographics and relation to co-morbidities.
Research methods
Key search terms such as “diabetes”, “foot ulcers”, “amputations” and “outcomes” 
were searched on PubMed/MEDLINE and Google Scholar. A follow-up of 12 mo, age 
> 18 and LEA post DFU were inclusion criteria. Paediatric patients were excluded. 
Two co-authors selected studies based on the inclusion criteria and search results were 
limited to the English language. A total of 22 publications with a total of 2334 patients 
were selected. There were no randomised controlled trials with the majority of studies 
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being cohort studies.
Research results
Our results show a significant re-amputation and mortality rates at 1, 3 and 5 years 
after initial LEA for DFU. A positive correlation was also noted for previous other 
major amputation and ischemic cardiomyopathy. We attempted to standardise 
patients for co-morbidities, however, this was not possible in a minority of studies. 
Therefore, future research should be aimed at delineating the nature of association 
between LEA post DFU and patient co-morbidities.
Research conclusions
Our systematic review and meta-analyses support our key hypotheses of a significant 
positive association of re-amputation, mortality and quality of life in our set of patients 
on a long-term basis. The pivotal purpose of this study is data to assist patient 
selection and decision-making. It also supports the uniformity of similar rates of re-
amputation and mortality in various studies globally with no significant outliers.
Research perspectives
Future research should be aimed at assessing the significance of co-morbidities on 
patients with DFU undergoing LEA. This will allow a closer risk stratification and aid 
patient decision-making individualised to their situation. In addition to this, as 
outcomes in diabetes mellitus often depend on patient compliance influenced by their 
socio-economic or cultural backgrounds, further studies are needed in these groups. 
The best methods for future studies would be larger, multi-center prospective studies.
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